FDA Limits Use of J&J Janssen COVID-19 Vaccine
The FDA limited authorized use of the J&J Janssen COVID-19 vaccine to certain individuals due to risk of thrombosis with thrombocytopenia syndrome.
The FDA limited authorized use of the J&J Janssen COVID-19 vaccine to certain individuals due to risk of thrombosis with thrombocytopenia syndrome.
Maureen Ferran, a virologist at the Rochester Institute of Technology, explains how this third authorized vaccine works and explores the differences between it and the Moderna and Pfizer–BioNTech vaccines that are already in use.
Johnson & Johnson is scrapping its investigational therapy for respiratory syncytial virus (RSV) and human metapneumovirus to the tune of a $900 million tax write-off.